WealthTrust Axiom LLC Invests $219,000 in IDEXX Laboratories, Inc. $IDXX

WealthTrust Axiom LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, Holdings Channel reports. The fund purchased 409 shares of the company’s stock, valued at approximately $219,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Mutual of America Capital Management LLC increased its stake in IDEXX Laboratories by 79.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after purchasing an additional 8,609 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in IDEXX Laboratories in the second quarter valued at $405,000. Plato Investment Management Ltd increased its position in shares of IDEXX Laboratories by 37.1% in the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after buying an additional 835 shares in the last quarter. Genesis Wealth Advisors LLC acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth $215,000. Finally, ORG Wealth Partners LLC purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $273,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $753.05 on Friday. The company has a market cap of $60.13 billion, a PE ratio of 62.70, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The stock has a 50-day moving average price of $666.95 and a two-hundred day moving average price of $605.05. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company posted $2.80 EPS. The company’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of several recent research reports. Jefferies Financial Group restated a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of IDEXX Laboratories in a research note on Tuesday. Piper Sandler reaffirmed a “neutral” rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Finally, UBS Group increased their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $730.50.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.